173 related articles for article (PubMed ID: 7694857)
1. Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice.
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
Eur J Pharmacol; 1993 Aug; 240(2-3):201-6. PubMed ID: 7694857
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO).
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1993 Mar; 264(3):1021-7. PubMed ID: 7680715
[TBL] [Abstract][Full Text] [Related]
3. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO).
Jiang Q; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1992 Aug; 262(2):526-31. PubMed ID: 1380079
[TBL] [Abstract][Full Text] [Related]
5. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists.
Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1994 Mar; 268(3):1107-13. PubMed ID: 7511163
[TBL] [Abstract][Full Text] [Related]
6. 14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists.
McLaughlin JP; Sebastian A; Archer S; Bidlack JM
Eur J Pharmacol; 1997 Feb; 320(2-3):121-9. PubMed ID: 9059844
[TBL] [Abstract][Full Text] [Related]
7. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
9. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
10. ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
Lohmann AB; Welch SP
Eur J Pharmacol; 1999 Dec; 385(2-3):119-27. PubMed ID: 10607867
[TBL] [Abstract][Full Text] [Related]
11. Spinal delta 2-, but not delta 1-, mu-, or kappa-opioid receptors are involved in the tail-flick inhibition induced by beta-endorphin from nucleus raphe obscurus in the pentobarbital-anesthetized rat.
Tseng LF; Tsai JH; Collins KA; Portoghese PS
Eur J Pharmacol; 1995 Apr; 277(2-3):251-6. PubMed ID: 7493616
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
13. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
14. Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse.
Ohsawa M; Mizoguchi H; Narita M; Chu M; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2000 Sep; 294(3):1106-11. PubMed ID: 10945866
[TBL] [Abstract][Full Text] [Related]
15. Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors.
Sakurada S; Takeda S; Sato T; Hayashi T; Yuki M; Kutsuwa M; Tan-No K; Sakurada C; Kisara K; Sakurada T
Eur J Pharmacol; 2000 Apr; 395(2):107-12. PubMed ID: 10794815
[TBL] [Abstract][Full Text] [Related]
16. Delta but not mu-opioid receptors in the spinal cord are involved in antinociception induced by beta-endorphin given intracerebroventricularly in mice.
Suh HH; Tseng LF
J Pharmacol Exp Ther; 1990 Jun; 253(3):981-6. PubMed ID: 2162954
[TBL] [Abstract][Full Text] [Related]
17. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice.
Narita M; Takahashi Y; Takamori K; Funada M; Suzuki T; Misawa M; Nagase H
Jpn J Pharmacol; 1993 May; 62(1):15-24. PubMed ID: 8393497
[TBL] [Abstract][Full Text] [Related]
18. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
Pacheco Dda F; Romero TR; Duarte ID
Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
[TBL] [Abstract][Full Text] [Related]
19. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties.
Jiang Q; Sebastian A; Archer S; Bidlack JM
Eur J Pharmacol; 1993 Jan; 230(1):129-30. PubMed ID: 7679076
[TBL] [Abstract][Full Text] [Related]
20. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
